Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 24700175)

1.

Association between upper digestive tract microbiota and cancer-predisposing states in the esophagus and stomach.

Yu G, Gail MH, Shi J, Klepac-Ceraj V, Paster BJ, Dye BA, Wang GQ, Wei WQ, Fan JH, Qiao YL, Dawsey SM, Freedman ND, Abnet CC.

Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):735-41. doi: 10.1158/1055-9965.EPI-13-0855. Epub 2014 Apr 3.

2.

Beta-diversity metrics of the upper digestive tract microbiome are associated with body mass index.

Lin SW, Freedman ND, Shi J, Gail MH, Vogtmann E, Yu G, Klepac-Ceraj V, Paster BJ, Dye BA, Wang GQ, Wei WQ, Fan JH, Qiao YL, Dawsey SM, Abnet CC.

Obesity (Silver Spring). 2015 Apr;23(4):862-9. doi: 10.1002/oby.21020. Epub 2015 Mar 9.

PMID:
25755147
3.

Current issues and future perspectives of gastric cancer screening.

Hamashima C.

World J Gastroenterol. 2014 Oct 14;20(38):13767-74. doi: 10.3748/wjg.v20.i38.13767. Review.

4.

Clinical significance in combined detection of serum pepsinogen I, pepsinogen II and carbohydrate antigen 242 in gastric cancer.

Yun L, Bin Z, Guangqi G, Ding L, Xingdang L, Biao H.

Hepatogastroenterology. 2014 Jan-Feb;61(129):255-8.

PMID:
24895832
5.

Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: a longitudinal study.

Tu H, Sun L, Dong X, Gong Y, Xu Q, Jing J, Long Q, Flanders WD, Bostick RM, Yuan Y.

Int J Cancer. 2015 Jan 15;136(2):425-34. doi: 10.1002/ijc.29005. Epub 2014 Jun 19.

PMID:
24895149
6.

Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: a monocentric cohort study in China.

Huang Z, Zhang X, Lu H, Wu L, Wang D, Zhang Q, Ding H.

BMC Gastroenterol. 2014 Apr 11;14:74. doi: 10.1186/1471-230X-14-74.

7.

Combining the serum pepsinogen level and Helicobacter pylori antibody test for predicting the histology of gastric neoplasm.

Choi HS, Lee SY, Kim JH, Sung IK, Park HS, Shim CS, Jin CJ.

J Dig Dis. 2014 Jun;15(6):293-8. doi: 10.1111/1751-2980.12144.

PMID:
24602176
8.

A brief overview of the 32nd Annual STP Symposium on the Toxicologic Pathology of the Digestive Tract and Pancreas.

Danilenko DM, Nambiar PR, Cesta MF.

Vet Pathol. 2014 Mar;51(2):541-4. doi: 10.1177/0300985813519133. Epub 2014 Jan 17. No abstract available.

9.

The value of serum pepsinogen levels for the diagnosis of gastric diseases in Chinese Han people in midsouth China.

Zhang XM, Li JX, Zhang GY, Li XH, Gu H.

BMC Gastroenterol. 2014 Jan 3;14:3. doi: 10.1186/1471-230X-14-3.

10.

A possible association of low pepsinogen I and pepsinogen I/II with low and high body weight in Japanese men.

Kutsuma A, Oshida H, Suwa K, Nakajima K.

Clin Biochem. 2014 Jan;47(1-2):126-8. doi: 10.1016/j.clinbiochem.2013.10.003. Epub 2013 Oct 11.

PMID:
24125879
11.

Serum ghrelin; a new surrogate marker of gastric mucosal alterations in upper gastrointestinal carcinogenesis.

Sadjadi A, Yazdanbod A, Lee YY, Boreiri M, Samadi F, Alizadeh BZ, Islami F, Fyfe V, Babaei M, Namazi MJ, Going JJ, Sotoudeh M, de Bock GH, Malekzadeh R, Derakhshan MH.

PLoS One. 2013 Sep 30;8(9):e74440. doi: 10.1371/journal.pone.0074440. eCollection 2013.

12.

Polymorphisms in genes coding for HSP-70 are associated with gastric cancer and duodenal ulcer in a population at high risk of gastric cancer in Costa Rica.

Ferrer-Ferrer M, Malespín-Bendaña W, Ramírez V, González MI, Carvajal A, Une C.

Arch Med Res. 2013 Aug;44(6):467-74. doi: 10.1016/j.arcmed.2013.08.008. Epub 2013 Sep 17.

PMID:
24051039
13.

Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer.

Yoshida T, Kato J, Inoue I, Yoshimura N, Deguchi H, Mukoubayashi C, Oka M, Watanabe M, Enomoto S, Niwa T, Maekita T, Iguchi M, Tamai H, Utsunomiya H, Yamamichi N, Fujishiro M, Iwane M, Takeshita T, Ushijima T, Ichinose M.

Int J Cancer. 2014 Mar 15;134(6):1445-57. doi: 10.1002/ijc.28470. Epub 2013 Oct 3.

PMID:
24009139
14.

Pepsinogen I and II expressions in situ and their correlations with serum pesignogen levels in gastric cancer and its precancerous disease.

Li P, He C, Sun L, Dong N, Yuan Y.

BMC Clin Pathol. 2013 Sep 2;13(1):22. doi: 10.1186/1472-6890-13-22.

15.

Serum gastrin and the pepsinogen I/II ratio as markers for diagnosis of premalignant gastric lesions.

Shafaghi A, Mansour-Ghanaei F, Joukar F, Sharafkhah M, Mesbah A, Askari K, Geranmayeh S, Mehrvarz A, Souti F, Sokhanvar H, Fakhrieh S, Aminian K, Yousefi-Mashhour M, Khosh-Sorur M, Rasoulian J.

Asian Pac J Cancer Prev. 2013;14(6):3931-6.

16.

Serum pepsinogens and Helicobacter pylori are not associated with esophageal squamous cell carcinoma in a high-risk area in China.

Xue L, Xing L, Wang J, Shen H, Cui J, Mi J, Wang J, Misumi J, Zhang X.

Tumori. 2013 Mar-Apr;99(2):134-8. doi: 10.1700/1283.14181.

17.

Predominant mucosal IL-8 mRNA expression in non-cagA Thais is risk for gastric cancer.

Yamada S, Kato S, Matsuhisa T, Makonkawkeyoon L, Yoshida M, Chakrabandhu T, Lertprasertsuk N, Suttharat P, Chakrabandhu B, Nishiumi S, Chongraksut W, Azuma T.

World J Gastroenterol. 2013 May 21;19(19):2941-9. doi: 10.3748/wjg.v19.i19.2941.

18.

[Risk of gastric cancer dependent on serological markers of atrophic gastritis: cohort study].

Reshetnikov OV, Openko TG, Simonova GI, Kurilovich SA, Maliushina SK, Ragino IuI, Voevoda MI.

Vopr Onkol. 2012;58(5):644-8. Russian.

PMID:
23600281
19.

Upper gastrointestinal microbiota and digestive diseases.

Wang ZK, Yang YS.

World J Gastroenterol. 2013 Mar 14;19(10):1541-50. doi: 10.3748/wjg.v19.i10.1541. Review.

20.

Are the serum biomarkers pepsinogen I and II good predictors for the detection of subjects with atrophic gastritis in areas that have different gastric cancer incidence?

Mohamadkhani A, Darvish Moghaddam S, Salmanroghani H, Allafsghari A, Yazdanbod A, Mirzaei M, Haj-sheykholeslami A, Bashiri J, Sadjadi A, Massarrat S.

Arch Iran Med. 2013 Apr;16(4):208-12. doi: 013164/AIM.003.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk